|
News
GP Pharm concludes final reports for preclinical studies of SarcodoxomeŽ
18-11-2008
Final reports for preclinical studies for GP Pharm’s Liposomal Doxorubicine Sarcodoxome® have been released. Those studies are related to one of the major safety improvements of GP Pharm’s formulation and were performed at Department of Human Toxicology, Faculty of Health, medicine and Live Sciences. University of Maastricht Comparison of the cardiotoxicity of Liposomal Doxorubicin GP Pharm with free doxorubicin in the mouse using ECG Telemetry Conclusions: Based on the results of this study, it can be conclude that Liposomal doxorubicin GP Pharm is less cardiotoxic than free doxorubicin. Lipocroman-6: Activity of a new antioxidant in a LPO (Lipid Peroxidation ) in vitro system. Conclusions: Based on the results of this study, it can be conclude that Lipocroman-6 reduces Lipid peroxidation in vitro.
| |
